Plasmacytoid dendritic cell (PDC) leukemia/lymphoma is a rare neoplasm presenting cutaneous lesions at the time of diagnosis, followed by dissemination to bone marrow, lymph nodes, and other lymphoid and nonlymphoid organs. Since these leukemic counterparts of human PDC are similar to normal PDC, we studied their chemokine receptor equipment and their migratory capacities. We found both in skin lesions and in invaded lymph nodes an expression by tumor cells of CXCR3, CXCR4, and CCR7, and the concomitant expression by cells in the microenvironment of their respective ligands CXCL9, CXCL12, and CCL19. Moreover, flow cytometry phenotype of leukemic PDC (LPDC) revealed an unexpected expression of CCR6. We show that fresh tumor cells are able to migrate in response to CXCR4, CCR2, CCR5, CCR6, and CCR7 ligands, and the ability of CXCR3 ligands to increase the responsiveness to CXCL12. IL-3-or virus-induced activation of LPDC leads to downregulation of CXCR3 and CXCR4, and upregulation of CCR7, associated with the loss of response to CXCL12, and the acquisition of sensitivity to CCL19. Altogether, these results suggest that the preferential accumulation of LPDC in the skin or lymph nodes could be orchestrated by CXCR3, CXCR4, CCR6, and CCR7 ligands, found in nontumoral structures of invaded organs.
Introduction
The initiation of the immune response is orchestrated by dendritic cells (DC) because of their great ability to capture, process, and present antigens in the appropriate context. This relies on the ability of circulating DC to home constitutively to peripheral tissues or to enter and migrate through inflamed tissues where they encounter antigens. On exposure to inflammatory stimuli, they travel to local lymph nodes through afferent lymph vessels, and undergo further maturation. 1 This DC traffic is allowed by the production of various chemokines according to the anatomic site or the inflammatory status of the tissue and by the expression of appropriate chemokine receptors by DC. Since their original identification, at least two distinct circulating DC subsets have been identified: myeloid DC (MDC) and plasmacytoid DC (PDC). The knowledge of the crucial role of MDC in the capture and processing of antigens and then in the priming of Th1 and Th2 responses has been reinforced by the studies of their migratory abilities. Indeed, blood MDC can sequentially migrate to CCR2 ligand or to others (CCR1, CCR5, CXCR1 ligands) and then to CCR6 ligand to reach the site of antigen exposure. 2 During a pathogen invasion, for instance, MDC capture antigens and then leave the tissues by downregulating CCR6 and upregulating CCR7 to move to lymphoid organs where CCR7 ligands are produced. [3] [4] [5] Thus, in the T-cell zone of lymph nodes, they activate naive T cells that differentiate in effector T cells, which return to the site of inflammation.
Such a dynamistic organization is not yet known about PDC. 6 PDC probably play a pivotal role between innate and adaptive immunity due to their ability to produce large amounts of IFNa, 7 and to induce the proliferation and differentiation of antiviral CD 8 þ and CD 4 þ T cells in response to virus. 8 In adults, PDC have been found predominantly in blood, 9 ,10 bone marrow, 10, 11 and thymus. 12, 13 Interestingly, in several inflammatory situations, PDC have been described in other lymphoid (reactive lymph nodes, 10,14-16 tonsils 17 ) and nonlymphoid organs (skin, [18] [19] [20] [21] [22] [23] mucosa 24 ). In reactive secondary lymphoid organs, PDC are found mainly nonactivated and located in T-cell area close to the postcapillary high endothelial venules (HEV) suggesting their entrance from blood stream. Expression of L-selectin (CD62L) 16 and a functional CXCR4 6, 25, 26 could be responsible for this anatomic localization. CD62L is an important molecule for tethering, rolling, and adhesion of lymphocytes to HEV, and CXCR4 is the receptor for CXCL12/SDF-1 produced by endothelial cells in secondary lymphoid organs. 26, 27 Furthermore, PDC express CXCR3 receptor for IFN-g-inducible chemokines (CXCL9/MIG, CXCL10/IP-10, and CXCL11/ITAC) 26 released by HEV during inflammation. 28 Recently, CXCR3 ligands have been shown to increase reactivity to the constitutive chemokine CXCL12, 26, 29 suggesting a role in PDC entry into reactive lymph nodes. At last, PDC could reach T-cell areas after expression of CCR7 following activation in response to the chemokine CCL19/MIP3b. 6 Although CXCR3 ligands and CXCL12 might also be involved in PDC recruitment in nonlymphoid tissues (skin and mucosa) where they can encounter antigens, no clear mechanism has been proposed. Moreover, although PDC express a distinct pattern of toll-like receptors allowing the response to different types of pathogens, [30] [31] [32] the site where they encounter pathogens (peripheral tissue vs lymph node) remains uncertain.
We have recently identified a leukemic counterpart of human PDC (LPDC), which is very similar to normal PDC in phenotype and function. 33, 34 However, most of the tumor cells expressed CD56 and granzyme B and they produce IFN-a and mature in response to virus, less efficiently than normal PDC.
PDC leukemia/lymphoma is a rare hematologic neoplasm, representing only 95 putative cases in the world literature. 35 A typical disease presentation consists in isolated cutaneous lesions at the time of diagnosis, followed by dissemination to bone marrow, lymph nodes, and other lymphoid and nonlymphoid organs within a few months. Skin lesions ranging from a few mm up to more than 10 cm highly invaded by tumor PDC were the most constant symptom of the disease, affecting more than 90% of the patients.
In this work, we wondered if the abilities of LPDC to move into the skin and lymph nodes could be explained by the expression of functional chemokine receptors specific for these anatomic sites.
Materials and methods

Patients
Nine patients (eight men and one woman from 8 to 82 years of age, mean ¼ 66 years) with a PDC leukemia/lymphoma (LPDC) are included in this study. 
Immunohistochemistry
The biopsies (invaded lymph nodes or skin) were frozen in liquid nitrogen and stored at À801C before use. They were sliced with a cryostat (7 mm) and processed for light microscopy and immunohistochemistry. Immunohistochemistry for detection of CXCR4 (12G5), CCR7 (2H4), CXCR3 (1C6/CXCR3) (BD Bioscience Pharmingen, San Diego, CA, USA), CXCL9 (49106.11), CCL19 (goat polyclonal antibody) (R&D Systems, Lille, France), CXCL12, 27 and CCL20 (308B7, Schering-Plough) was performed with a standard technique using the avidinbiotin peroxidase complex method using a Histo Stain Plus Broad Spectrum Kit (Zymed, Cliniscience). A control section omitting the primary antibody was included for each tissue specimen. The intensity of the red-stained cells was appreciated by comparison with the control section. 
Flow cytometry
Modulation of chemokine receptors expression on cultured tumor cells
Tumor cells from five patients were cultured at 10 6 cells/ml for 2 days in complete 10% FCS RPMI 1640 medium either with IL-3 (three cases, 10 ng/ml), or with IL-3 (10 ng/ml) plus recombinant human soluble CD40L (two cases, 1 mg/ml, Alexis), or with formaldehyde-inactivated influenza virus (five cases, 137 ng/ml hemagglutinin, strain A/New Caledonia/20/99 IVR116, Aventis Pasteur, Val de Reuil, France). On day 2, cells were harvested and phenotypic analyses were performed. The analysis of the expression of CXCR3, CXCR4, CCR6, and CCR7 was performed by flow cytometry as described for fresh cells.
Chemotaxis assay in transwells
Chemotaxis assays were performed in three cases where the tumor cells represented more than 90% of the tumor sample. Tumor cells were preactivated by a 2-day culture with IL-3 or influenza virus. Migration assays were carried out using transwells (6.5 mm diameter, COSTAR, Cambridge, MA, USA) with 5 Â 10 5 cells/well as described. 2 Fresh or preactivated LPDC populations were washed, preincubated for 1 h at 371C and then placed for 2 h in 5 mm pore size inserts and the migration was revealed by double staining CD45RA þ /HLA-DR þ tumor cells. Chemokines were used at 1 mg/ml (optimal concentration). The results were expressed as migration index (ratio chemokine/medium). In all, o10% variations were observed in these experiments. Mean number of spontaneously migrating cells were 90, 942, and 907, for fresh, IL-3-, and virusactivated cells, respectively. The results are representative of two independent experiments.
Results
Apart from the CCR6 expression, LPDC expressed a comparable pattern of chemokine receptors as normal PDC
It is now well known that MDC trafficking is orchestrated both by the selective production of chemokines in different anatomic sites and by the corresponding selective expression of chemokine receptors. We first analyzed the in situ expression of the main couples of ligand/receptors already described for MDC and PDC migration on skin and lymph node biopsies from patients with PDC leukemia/lymphoma ( Figure 1 and Table 1 ). PDC can be distinguished by their morphology and their positivity with CD123 and BDCA-2 stainings (data not shown).
We found that CXCR3 and CXCR4 were highly expressed by LPDC in both tissues (Figure 1b , c, k and l) and that their respective ligands, CXCL9 and CXCL12, were both expressed in sweat glands or follicles in skin biopsies or in vessels in lymph node biopsies (Figure 1f , g, o and p, see arrows). CCR7 was found less expressed by PDC (Figure 1d and m) and one of its ligands, CCL19, was also produced in sweat glands or follicles in skin biopsies or in infiltrating cells in lymph node biopsies ( Figure 1h and q, see arrows) . Moreover, the same pattern of expression was also found for the CCR6 ligand (Figure 1i and r) . Unfortunately, for technical reasons, the sensitivity of the immunostaining did not allow detection of CCR6 expression in these biopsies.
We next examined by flow cytometry the expression of six CC chemokine receptors (CCR1, CCR2, CCR3, CCR5, CCR6, CCR7) and five CXC chemokine receptors (CXCR1, CXCR2, CXCR3, CXCR4, CXCR5) on LPDC isolated from blood (n ¼ 2), lymph nodes (n ¼ 2), and bone marrow (n ¼ 4) from patients with PDC leukemia/lymphoma ( Figure 2 and Table 2) .
As normal PDC, all LPDC specimens expressed CXCR3 and CXCR4 at relatively high levels, and CCR2 and CCR5 at significant levels however with a more heterogeneous expression. Interestingly, in contrast to circulating blood normal PDC and MDC, we found CXCR2, CCR6, and CCR7 expressed in 60, 40, and 50% of the cases, respectively. CCR1, CCR3, CXCR1, and CXCR5 were not or rarely expressed, as in normal PDC. Expression of CXCR3, CXCR4, CCR7, CXCL9, CXCL12, CCL19, and CCL20 in LPDC-invaded tissues. CXCR3, CXCR4, and CCR7 are expressed by LPDC both in the invaded lymph node (b-d) and skin (k-m). CXCL9 and CXCL12 are expressed in the blood vessels of LPDC-invaded lymph node (f, g, arrows), and CCL19 and CCL20 are expressed by nontumoral infiltrating cells (h, i, arrows). In the skin, CXCL9, CXCL12, CCL19, and CCL20 are found on sweat glands (o-r, arrows). Immunohistochemistry was performed on cryopreserved sections of invaded lymph nodes or skin from patients with PDC-derived leukemia/lymphoma (initial magnification: a-c, h-j, Â 40; d-g, k-n, Â 20); control section omitting the primary antibody is shown for each tissue specimen (a, e, j, n). Table 1 In situ expression of chemokines and chemokine receptors There was apparently no distinct expression profile of chemokine receptors according to the anatomic sites from which LPDC were isolated.
LPDC migration to CXCR3, CXCR4, CCR2, CCR5, CCR6, and CCR7 ligands
Migration experiments were performed with LPDC#7, #8, and #15 because of the availability of cells. The results presented in Figure 3a -d show that a relatively high proportion of LPDC migrated in response to CXCR4 ligand (CXCL12/SDF-1), whereas they did not respond to CXCR3 ligand (CXCL9/MIG). LPDC showed little response to CCL19/MIP3b according to their low level of CCR7 expression. Interestingly, LPDC that expressed CCR6 (LPCD#7) migrated in response to CCL20/ MIP3a. We also found that LPDC#7 responded to CCR2 ligand (CCL13/MCP-4; migration index ¼ 55) and to CCR5 ligand (CCL5/RANTES; migration index ¼ 8) (not shown). It has been recently shown on normal PDC that CXCR3 ligands were able to increase their response to CXCR4 ligand, 26, 29 and we wondered if LPDC share the same characteristics. We studied the chemotactic response of LPDC to CXCL12 in the presence of CXCL9 or CXCL10. The results presented in Figure 3e show that the CXCR3 ligands greatly increased LPDC responsiveness to CXCL12 since in the presence of CXCR3 ligands an identical migration index was obtained with a 30-fold lower concentration of CXCL12.
Chemokine responsiveness of LPDC was modulated after culture with IL-3 and influenza virus
The traffic of MDC is regulated by sequential expression of chemokine receptors according to their activation status. 3, 4 In order to determine if culture or activation could modify the migratory capacities of LPDC, we examined the functional expression of receptors for CXCR3, CXCR4, CCR6, and CCR7 ligands after culture with IL-3 or influenza virus. We have previously shown that LPDC are rescued from apoptosis and activated with IL-3 and that their viral activation induced the expression of activation markers and the production of IFNa. 33, 38 We found that expression of CXCR3 and CXCR4 was dramatically decreased after 2-day cultures either in the Expression of CCR2, CCR5, CCR6, CXCR3, and CXCR4 on fresh LPDC. Surface expression of chemokine receptors was analyzed by flow cytometry. These representative data were obtained with fresh cells isolated from the blood of patient LPDC#7.
Table 2
Expression of chemokine receptors by leukemic and normal PDC (Figure 4 and Table 3 ). The downmodulation of CXCR4 was accompanied by a complete loss of LPDC responsiveness to CXCL12 (Figure 3b ). CCR6
expression was increased by IL-3 culture and to a lesser extent by virus activation. Whereas uncultured LPDC#7 yet expressed functional CCR6, for other cells only LPDC cultured with IL-3 responded to CCR6 ligand used at 1000 ng/ml in chemotaxis assay (Figure 3c ). Of note, with LPDC#7, in the presence of lower doses (100 ng/ml) of CCL20, migration index of IL-3-cultured LPDC and virus-cultured LPDC was 13 and 5.8, 
Figure 3
Migration of LPDC. Fresh LPDC do not migrate to CXCL9/MIG (a) but respond to CXCL12/SDF-1 (b). When expressing CCR6, LPDC are able to migrate in response to CCL20/MIP3a (c). The slight migration of fresh cells to CCL19/MIP3b is greatly increased when the cells are matured upon culture with either IL-3 or influenza virus for 2 days (d). CXCR3 ligands induce a sensitizing effect of LPDC allowing their migration to lower CXCL12/SDF-1 concentrations (e). Here, CXCR3 ligands (1 mg/ml) were added with the cells in the upper wells, whereas CXCL12 was in the lower wells.
Figure 4
Expression of chemokine receptors by mature LPDC. Maturation of LPDC by IL-3 or influenza virus induces downregulation of CXCR3 and CXCR4 and upregulation of CCR6 and CCR7 expression, respectively. Analysis was performed by flow cytometry and compared to fresh cells. LPDC#7 were used in this representative experiment.
Table 3
Modulation of chemokine receptors on leukemic PDC after a 2-day activation 
Percentages of positive tumor cells and MFI (in parentheses) were determined by flow cytometry, on both fresh and 2-day cultured LPDC isolated from bone marrow (LPDC#8 and #15) and blood (LPDC#7, #10, and #19). LPDC were gated according to their CD56 + or CD45 low expression. ND: not done. a IL-3+CD40L.
Migratory capacities of leukemic plasmacytoid dendritic cells N Bendriss-Vermare et al respectively (not shown). Thus, although the migration index was identical between fresh and cultured LPDC at 1000 ng/ml of CCL20, IL-3-cultured LPDC migrated more efficiently to lower doses of CCL20 than fresh or virus-activated LPDC. This observation may result from the increase in the CCR6 expression level on LPDC cultured with IL-3 (mean fluorescence intensity (MFI) ¼ 460) as compared to fresh (MFI ¼ 30) and virus-cultured (MFI ¼ 69) cells (Table 3) . Thus, the upregulation of CCR6 results in a higher propensity of cultured LPDC to migrate to lower doses of CCL20, in particular upon culture with IL-3, which strongly decreases the threshold of CCL20 sensitivity. The modulation of chemokine receptors by culture was also evidenced by the upregulation of CCR7 in both systems, and cultured LPDC became sensitive to CCL19 (Figure 3d) . Furthermore, we found that culture with IL-3 or virus induced downregulation of CCR2 and CCR5 expression on LPDC#7, which leads to an LPDC hyporesponsiveness to CCR2 ligand (CCL13/MCP-4; migration index p3) and to CCR5 ligand (CCL5/RANTES; migration index p3) (not shown).
Discussion
In this work, we used cells obtained from patients with PDC leukemia/lymphoma. These tumor cells are very similar to normal PDC, 33 lacking lineage markers (CD3, CD19, CD13, CD14, CD11c) and expressing CD4, HLA-DR, CD45RA, high levels of CD123, blood dendritic cell antigen-2 (BDCA-2), and BDCA-4.
38 LPDC expressed mRNA coding for pre-Ta and lambda-like chains, like normal PDC, and a large amount of lymphoid-related transcripts. 34 Besides their ability to produce IFN-a, we found recently that LPDC become fully competent antigen-presenting cells after maturation by IL-3 and CD40L or virus. Moreover, they are able to capture, process, and present exogenous and virus-derived antigens to activate CD4 þ and CD8 þ T-cell clones. 38 From a clinical point of view, the most constant symptom of the PDC leukemia/lymphoma disease consists in skin lesions where LPDC infiltrating the dermis represent the main cell population. 35, 36 It is noticed from diagnosis, and represents the main cause of the first medical advice. In several observations, only these cutaneous lesions were described. This unexpected localization of tumoral PDC and the availability of tumor cells from other sites led us to study the expression of functional chemokine receptors to better understand their traffic into the body.
We found that LPDC share with normal PDC very similar properties in terms of cell migration potential. Indeed, they were negative for CCR1, CCR3, CXCR1, and CXCR5, whereas they expressed CCR2, CCR5, CXCR2, CXCR3, and CXCR4. Moreover, LPDC migrated in response to CXCL12, whereas they were not able to migrate to a CXCR3 ligand, CXCL9. We and others recently 26, 29 showed that CXCR3 ligands increased the responsiveness of normal PDC to CXCL12. We have demonstrated here that the CXCR3 ligands CXCL9 and CXCL10 decreased the threshold of CXCL12 sensitivity of tumoral PDC, confirming the close relationship between human normal and tumoral PDC. Interestingly, we found that CXCR3 and CXCR4 are expressed in situ by LPDC in lymph nodes and skin and that CXCL9 and CXCL12 are also produced in situ by perivascular or glandular cells. Thus CXCL12 in combination with CXCR3 ligands might induce the migration of LPDC both in lymph nodes and skin. CXCL12 has been described to be produced by endothelial cells in lymph nodes and in skin in inflammatory situations. 26, 27 Moreover, in a mouse model, it has been shown that CXCL12 is sufficient to induce cell migration of human PBL from the murine circulation into human lymph node transplants. 39 CXCR3 ligands were shown to be produced upon activation by HEV 28 and epidermal and dermal cells of the skin. 40 Furthermore, the chemokine receptor CXCR3 was proposed to play a role in PDC recruitment to skin in lupus as levels of its ligand CXCL10 are increased in patients. 23 Thus, after an immunological event not yet defined, the production of CXCR3 ligands may decrease the threshold of CXCL12 sensitivity of circulating LPDC, leading to efficient LPDC recruitment to the inflammatory site of constitutive CXCL12 production. It has also been shown that accumulation of PDC in cutaneous lesions of lupus erythematosus patients 22 as well as in nasal mucosa of experimentally elicited allergic rhinitis 24 correlated with the expression of CD62L/L-selectin ligands, PNAd, on dermal and mucosal vascular endothelium. These observations suggest that CD62L þ PDC may be recruited to inflamed peripheral tissues by the same adhesion molecules that normally mediate their extravasation in secondary lymphoid organs. 7, 29 Expression of Lselectin (CD62L) by tumoral PDC 33 may play an important role to cross the endothelial barrier and reach the inflamed lymph node. At last, intradermal injection of treponemal lipoproteins in healthy volunteers induces enrichment of CLA þ CCR5 þ PDC in blister fluids reflecting the expression of receptors for these molecules (ie E-and P-selectins) by activated vascular endothelium and suggesting a role of inflammatory CCR5 ligands (Rantes, MIP1a/b). 20 Thus, CLA and CCR5 could also contribute to LPDC traffic to skin. Surprisingly, CCR6 ligand was found both in skin and lymphoid organ and response to CCL20 was observed with CCR6 þ nonactivated or activated LPDC. Until now, no studies have described functional expression of CCR6 on PDC. CCR6 is expressed by immature myeloid DC 41 and is crucial for their recruitment to the skin, the site of CCL20 production. 2, 42, 43 It could be suggested that expression of CCR6 by LPDC endows these cells with the ability to migrate from blood to the skin. Furthermore, we observed that normal PDC, like LPDC, acquire CCR6 and CCL20 responsiveness in culture with IL-3. However, only LPDC acquire CCR6 in response to virus activation that does not induce CCR6 on normal PDC (Bendriss-Vermare et al, manuscript in preparation), suggesting that CCR6 expression could be differentially regulated between these two populations of PDC. The differences in CCR6 expression and regulation between the leukemic and normal PDC could account in part for the ability of the LPDC to track to the skin. Further experiments are needed to formally decipher this hypothesis. Altogether, this may suggest that CCL20 and CCR6 could play a role in some pathologic situations, [18] [19] [20] 22, 24 where normal PDC accumulation has been recently described. The role of CCR4 and CCR10 in this LPDC trafficking to skin remains to be investigated as these chemokine receptors have been demonstrated to be involved in skin-specific CD 4 þ T-lymphocyte homing. 44 We also detected CCR7-positive LPDC, associated with the production of CCL19 in both tissues. Moreover, upon viral or IL-3 activation, LPDC upregulated CCR7 and responded to CCL19. The unexpected expression of CCR7 in skin could be due to tumoral origin of PDC. However, like for myeloid DC, CCR7 expression on PDC could illustrate their ability to migrate via the lymph vessels from peripheral tissues to lymph nodes. However, the expression of CCL21/6Ckine, an other CCR7 ligand, has recently been reported in dermal endothelial cells. 45 Thus, expression of CCL19 or CCL21 could contribute to the migration of LPDC to the skin in this peculiar disease.
Thus, expression of functional CCR6 and CCR7 on LPDC suggests that both CCL20 and CCL19, in combination with CXCR3 ligands and CXCL12, could contribute to the traffic of LPDC in the PDC leukemia/lymphoma patients. CCR6 expression might target cells into the skin, which represents the first and the most frequent tumoral localization. Accumulation of cells in the skin could result from both in situ production of chemokines and tumoral proliferation. Indeed, the expression of Ki67 antigen revealed that 15-30% of malignant cells were cycling. However, tumor cells invade other tissues like lymph nodes in 50% of the cases. Expression of CCR7 could explain this localization. Both CXCR3 and CXCR4 may contribute to the recruitment of tumor cells in the skin and lymph nodes but certainly also in other tissues characterizing the disease. 35 Two recent studies 20, 24 concerning experimental recruitment of PDC in the skin or mucosa following antigen exposure suggest that normal PDC can reach, probably from blood, the effector sites with direct antigen exposure. It would be of particular interest to analyze the chemokine production in the tissue and the chemokine receptor profile of the recruited PDC in these models.
